Retatrutide adds a third receptor, glucagon, and has produced larger weight loss in matched-duration trials (28.7% at 68 weeks in TRIUMPH-4 vs approximately 22.5% at 72 weeks in SURMOUNT-1)
At Tucson Wellness MD, we are dedicated to guiding you through this process with safety and precision
These examples show how syringe units may change depending on the concentration
Long-Term Success Maintaining weight loss long term often requires more than just GLP-1s
Remaining Scope for Side-Effect Improvement Retatrutide is a triple-action therapy that, like Lillys Mounjaro and Zepbound drugs, targets glucagon-like peptide-1, or GLP-1, and glucose-dependent insulinotropic polypeptide, or GIP, while also acting on the glucagon receptor
Mechanistic analyses reveal glucagon receptor activation plays a crucial role through increased hepatic fatty acid oxidation and reduced de novo lipogenesis